Pillary vs poorly differentiated), age, and sorafenib treatment, but not BRAF
Pillary vs poorly differentiated), age, and sorafenib treatment, but not BRAF or RAS mutation status, were independently prognostic for PFS advantage (Appendix D, Table D3). Similarly, mutation status was not…